Últimas noticias sobre HyperBlock (OTC:HYBOF) Bolsa

HyperBlock Inc is a diversified crypto leader. The company helps individuals and businesses to create, safeguard, manage and grow crypto assets. It mines Bitcoin, Bitcoin Cash, Dash, Zcash, Litecoin, and Ethereum. The company generates its revenue through Mining-as-Service hash rate sales, hosted mining and server sales.

HyperBlock Inc

CIBC analyst Jacob Bout maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Outperformer and raises the price target from $59 to $63.

News

Price Target

Analyst Ratings

MEOH

CIBC Maintains Outperformer on Methanex, Raises Price Target to $63

In the last three months, 13 analysts have published ratings on KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $20.65, with a high estimate of $23.00 and a low estimate of $18.00. This upward trend is apparent, with the current average reflecting a 2.23% increase from the previous average price target of $20.20.
<img src="https://www.benzinga.com/files/images/story/2025/1738609267_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive KeyCorp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vivek Juneja</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$18.50</td>
<td>-</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brian Foran</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$19.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to KeyCorp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KeyCorp compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for KeyCorp's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into KeyCorp's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KEY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on KeyCorp analyst ratings.</a>
<h2>Discovering KeyCorp: A Closer Look</h2>
With assets of over $180 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
<h3>KeyCorp: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, KeyCorp showcased positive performance, achieving a revenue growth rate of 25.08% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: KeyCorp's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -34.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): KeyCorp's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.86%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.15%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: KeyCorp's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.91.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

13 Analysts Have This To Say About KeyCorp

During the last three months, 6 analysts shared their evaluations of FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $21.33, a high estimate of $22.00, and a low estimate of $21.00. Witnessing a positive shift, the current average has risen by 6.01% from the previous average price target of $20.12.
<img src="https://www.benzinga.com/files/images/story/2025/1738609251_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of FS KKR Capital's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Bryce Rowe</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$21.50</td>
<td>-</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Bryce Rowe</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.50</td>
<td>$20.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to FS KKR Capital. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FS KKR Capital compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for FS KKR Capital's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of FS KKR Capital's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FSK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on FS KKR Capital analyst ratings.</a>
<h2>Delving into FS KKR Capital's Background</h2>
FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.
<h3>A Deep Dive into FS KKR Capital's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining FS KKR Capital's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -38.41% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: FS KKR Capital's net margin excels beyond industry benchmarks, reaching 94.12%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): FS KKR Capital's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.39%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): FS KKR Capital's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: FS KKR Capital's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.21.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into FS KKR Capital Stock: Analyst Perspectives (6 Ratings)

7 analysts have shared their evaluations of Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $142.29, with a high estimate of $155.00 and a low estimate of $125.00. This current average has increased by 1.64% from the previous average price target of $140.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738609241_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Steel Dynamics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Christopher LeFemina</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Christopher LeFemina</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$125.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Alexander Hacking</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Andrew Jones</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$149.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mike Harris</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$155.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Steel Dynamics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steel Dynamics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Steel Dynamics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steel Dynamics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steel Dynamics analyst ratings.</a>
<h2>About Steel Dynamics</h2>
Steel Dynamics Inc operates scrap-based steel minimills with roughly 16 million tons of annual steel production capacity. The company's segment includes steel operations, metals recycling operations, steel fabrication operations, Aluminum Operations Segment, and others. It generates maximum revenue from the steel operations segment.
<h3>Breaking Down Steel Dynamics's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Steel Dynamics's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -10.81% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.35%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Steel Dynamics's ROE excels beyond industry benchmarks, reaching 2.3%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Steel Dynamics's ROA stands out, surpassing industry averages. With an impressive ROA of 1.36%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Steel Dynamics's debt-to-equity ratio is below the industry average. With a ratio of 0.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STLD

What Analysts Are Saying About Steel Dynamics Stock

Analysts' ratings for Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) over the last quarter vary from bullish to bearish, as provided by 35 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">22</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">8</td>
<td align="right">16</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $99.31, a high estimate of $115.00, and a low estimate of $88.00. This current average has increased by 8.79% from the previous average price target of $91.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1738609229_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Walmart among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$111.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$94.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$89.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Dean Rosenblum</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$102.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Walmart. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Walmart compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Walmart's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Walmart's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WMT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Walmart analyst ratings.</a>
<h2>Get to Know Walmart Better</h2>
Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.
<h3>Walmart's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Walmart's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 5.46%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.
Net Margin: Walmart's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.31%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Walmart's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.77% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Walmart's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.7.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Walmart Stock: A Deep Dive Into Analyst Perspectives (35 Ratings)

8 analysts have shared their evaluations of OneMain Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $60.62, with a high estimate of $65.00 and a low estimate of $57.00. Marking an increase of 1.52%, the current average surpasses the previous average price target of $59.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1738609221_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive OneMain Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Kyle Joseph</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Michael Kaye</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$59.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Kyle Joseph</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$57.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to OneMain Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of OneMain Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of OneMain Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into OneMain Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OMF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OneMain Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind OneMain Holdings</h2>
OneMain Holdings Inc is engaged in nonprime consumer finance companies in the United States and is one of only a few companies in the consumer installment lending industry. It formed after a transaction brought together two branch-based consumer finance companies with complementary strategies and locations. Its services include providing personal loan products, offering credit and noncredit insurance, servicing loans, pursuing strategic acquisitions and dispositions of assets and businesses, and on occasion, establishing joint ventures or forming strategic alliances. The company's one reportable segment is consumer and insurance. In addition to hundreds of branches, the company also has an online business. The main source of revenue is net interest income.
<h3>OneMain Holdings's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining OneMain Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.06% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: OneMain Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 10.61%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): OneMain Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.94%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.49%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: OneMain Holdings's debt-to-equity ratio surpasses industry norms, standing at 6.72. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing OneMain Holdings: Insights From 8 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $243.44, along with a high estimate of $270.00 and a low estimate of $210.00. Observing a downward trend, the current average is 2.62% lower than the prior average price target of $250.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738609211_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive IQVIA Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$235.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$261.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$212.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$248.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IQVIA Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of IQVIA Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of IQVIA Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into IQVIA Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IQV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IQVIA Hldgs analyst ratings.</a>
<h2>All You Need to Know About IQVIA Hldgs</h2>
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
<h3>IQVIA Hldgs: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, IQVIA Hldgs showcased positive performance, achieving a revenue growth rate of 4.28% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IQVIA Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.17%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): IQVIA Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.06%, the company showcases efficient use of assets and strong financial health.
Debt Management: IQVIA Hldgs's debt-to-equity ratio surpasses industry norms, standing at 1.97. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For IQVIA Hldgs's Future

Citigroup analyst Bryan Burgmeier maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Buy and raises the price target from $242 to $255.

Citigroup Maintains Buy on Waste Management, Raises Price Target to $255

In the current market session, Arbor Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) share price is at $13.41, after a 0.15% increase. Moreover, over the past month, the stock decreased by 1.69%, but in the past year, spiked by 6.77%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1738609208_0.png" alt="Past Year Chart" />

<h3>Arbor Realty Trust P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Arbor Realty Trust has a lower P/E than the aggregate P/E of 10.48 of the Mortgage Real Estate Investment Trusts (REITs) industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1738609208_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Arbor Realty Trust

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and raises the price target from $205 to $215.

ABBV

Citigroup Maintains Buy on AbbVie, Raises Price Target to $215

Citigroup analyst Ariel Rosa maintains C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Buy and lowers the price target from $130 to $124.

CHRW

Citigroup Maintains Buy on C.H. Robinson Worldwide, Lowers Price Target to $124

IonQ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares rebounded Monday after initially trading lower alongside other quantum computing stocks. The stock, which was <a href="https://www.benzinga.com/news/contracts/25/01/42951228/whats-going-on-with-ionq-stock-today-3">down nearly 10% earlier</a> in the session, bounced back following an article detailing Bill Gates' comments on the timeline for useful quantum computing. 
What To Know: The sector potentially came under pressure after Nvidia CEO Jensen Huang suggested at CES 2025 last month that practical quantum computing could still be 15 to 30 years away. His remarks triggered a selloff, with some quantum stocks falling more than 40%. Meta CEO Mark Zuckerberg echoed similar skepticism in a podcast, calling quantum computing &#8220;still quite a ways off from being a truly practical paradigm.&#8221;
Gates spoke on <a href="https://finance.yahoo.com/news/bill-gates-theres-a-possibility-quantum-computing-will-become-useful-in-3-to-5-years-152007398.html">Yahoo Finance's Opening Bid podcast</a>, he said there&#8217;s a possibility that quantum breakthroughs could happen within three to five years, allowing systems to reach enough logical qubits to solve difficult problems. He acknowledged that the field is uncertain but pointed out that Microsoft, where he remains involved, is actively working on quantum computing and expects to release what it calls "the world's most powerful quantum machine" later this year.
IonQ also announced a $21.1 million research contract with the U.S. Air Force Research Lab to develop quantum network infrastructure, furthering its previous $54.5 million agreement with the military. The stock initially dropped despite the news but reversed course after Gates' comments gained attention. Gates, through his Breakthrough Energy venture, has previously invested in IonQ.
While the broader quantum sector remains volatile, IonQ is holding up better than its peers. D-Wave Quantum (QBTS) and Rigetti Computing (RGTI), two other heavily traded quantum names, are still down sharply this year. Rigetti, despite a massive run-up in 2024, remains under pressure after its CEO warned that significant commercial sales are still years away.
IONQ Price Action: IonQ shares were up 4.65% at $41.32 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133422/Screenshot-2025-02-03-at-13.33.57-1024x530.png" alt="" class="wp-image-763218" style="width:404px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133422/Screenshot-2025-02-03-at-13.33.57-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133422/Screenshot-2025-02-03-at-13.33.57-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133422/Screenshot-2025-02-03-at-13.33.57-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133422/Screenshot-2025-02-03-at-13.33.57.png 1525w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/25/02/43442997/dogwifhat-down-18-despite-grammy-hype-this-hats-not-going-anywhere">Dogwifhat Down 18% Despite Grammy Hype: &#8216;This Hat&#8217;s Not Going Anywhere&#8217;</a></li>
</ul>
Image Via Shutterstock.

Movers

IONQ

IonQ Stock Rebounds After Initial Selloff: What's Going On?

Citigroup analyst Jason Bazinet maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Buy and raises the price target from $63 to $82.

RBLX

Citigroup Maintains Buy on Roblox, Raises Price Target to $82

JP Morgan analyst Patrick Baumann maintains W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) with a Neutral and lowers the price target from $1125 to $1100.

JP Morgan Maintains Neutral on W.W. Grainger, Lowers Price Target to $1100

JP Morgan analyst Melissa Wedel maintains WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) with a Underweight and lowers the price target from $10 to $9.5.

JP Morgan Maintains Underweight on WhiteHorse Finance, Lowers Price Target to $9.5

Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) are duking it out for investor attention with <a href="https://www.benzinga.com/earnings">fourth-quarter earnings</a> being reported on Tuesday.
Both pharmaceutical heavyweights have very different technical setups, leaving investors to wonder which stock will have the upper hand.
Let's break down the charts and what the technical signals are saying about each company as they prepare to report.
<h1 class="wp-block-heading">Merck Stock's Mixed Signals: Bullish Short-Term, But Long-Term Resistance Looms</h1>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM.png" alt="" class="wp-image-763045" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Merck stock has shown some solid short-term strength, with its stock price of $98.90 comfortably sitting above its eight-day and 20-day simple moving averages (SMAs) of $97.81 and $98.64, respectively. These short-term buying signals, along with a neutral Relative Strength Index (RSI) of 50.39, suggest a continuation of the current trend, barring any earnings surprises.
However, the story changes when looking at Merck stock&#8217;s long-term trend. Its 50-day SMA of $99.64 and 200-day SMA of $114.28 are higher than its stock price, indicating that the stock may face resistance moving forward. Merck&#8217;s Moving Average Convergence Divergence (MACD) of a negative 0.47 suggests bearish momentum in the near term, adding an element of risk.
On the flip side, analysts are bullish on Merck with a <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">consensus target of $124</a>, representing an implied upside of 20.25%. That positive outlook could be enough to offset the short-term technical pressure, making Merck stock a bit of a mixed bag heading into earnings.
Read Also: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
<h1 class="wp-block-heading">Pfizer Stock's Bearish Downtrend: Can It Overcome The Struggles?</h1>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM.png" alt="" class="wp-image-763046" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
In stark contrast, Pfizer stock is looking much weaker technically. The stock has been firmly entrenched in a bearish trend, with its share price sitting below its five-, 20- and 50-day exponential moving averages (EMAs), signaling ongoing selling pressure. Pfizer stock at $26.30 has eight-day SMA at $26.51 and the 20-day SMA at $26.56, both signals pointing to potential further downside.
Pfizer stock's 50-day SMA of $26.15 provides some minor support, but overall, the chart points to more trouble ahead. The MACD indicator of 0.04 shows only a glimmer of bullish potential, while the RSI of 47.61 reinforces the neutral sentiment surrounding the stock. While there's a chance for some short-term recovery, Pfizer's overall trajectory looks weaker than Merck's.
Despite the challenges, Pfizer's analyst <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">consensus price target</a> is $36.74, offering an implied upside of 13.80%. However, with the Pfizer stock trading significantly below its 200-day SMA of $27.87, it's clear Pfizer has a tough road ahead.
<h1 class="wp-block-heading">Merck Vs. Pfizer: Who Will Win The Earnings Showdown?</h1>
When it comes to earnings, Merck's solid analyst outlook and bullish short-term signals seem to give it the edge over Pfizer, which is struggling with technical bearishness. 
While both stocks face risks, Merck's upside potential, supported by a 20% price target boost from analysts, makes it the more promising candidate for investors looking for stability and growth. 
Pfizer, on the other hand, remains a riskier play, though it does offer some upside potential if it can overcome its technical hurdles.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a></li>
</ul>
Photo: Merck: Zah108; Pfizer: Vadi Fuoco

Biotech

Health Care

Technicals

Previews

Trading Ideas

General

Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?

JP Morgan analyst Tami Zakaria maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Overweight and lowers the price target from $300 to $295.

JP Morgan Maintains Overweight on Illinois Tool Works, Lowers Price Target to $295

As of Feb. 3, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Ecopetrol SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>)</h3>
<ul>
<li>On Monday, Ecopetrol disclosed that Ecopetrol Permian LLC and Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) have planned to extend the development plan for Rodeo Midland Basin in the Permian Basin (Texas, USA). The agreement between Ecopetrol Permian and Occidental Petroleum, under the joint venture formed in July 2019, includes a drilling plan for 34 wells to be executed between April 2025 and June 2026, in addition to the ongoing wells planned for early 2025.. The company's stock surged around 16% over the past month and has a <a href="https://www.benzinga.com/quote/EC">52-week high of $12.90</a>.</li>
<li>RSI Value: 71.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>EC Price Action: Shares of Ecopetrol gained 3.1% to trade at $9.58 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Core Natural Resources Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNR#NYSE">CNR</a>)</h3>
<ul>
<li>On Jan. 31, Jefferies analyst Christopher LeFemina initiated coverage on Core Natural Resources with a Hold rating and announced a price target of $93. The company's stock gained around 825% over the past five years and <a href="https://www.benzinga.com/quote/CNR">has a 52-week high</a> of $134.14.</li>
<li>RSI Value: 70.6</li>
<li>CNR Price Action: Shares of Core Natural Resources fell 3.9% to trade at $86.92 on Monday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Short Ideas

Top 2 Energy Stocks That May Fall Off A Cliff In February

JP Morgan analyst Casey Woodring maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $280 to $265.

ICLR

JP Morgan Maintains Overweight on Icon, Lowers Price Target to $265

HCW Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares are trading higher on Monday after the company announced clearance from the Food and Drug Administration (FDA) for its Phase 1<a href="https://www.benzinga.com//node/43430431"> trial of HCW9302</a>.
The Details: The company&#8217;s HCW9302 is a potential treatment for moderate-to-severe alopecia areata, which is an autoimmune disease. Currently, there are no curative FDA-approved treatments for the disease.
The Phase 1 trial aims to establish a safe and effective dose of HCW9302. If successful, the company will proceed with Phase 2 studies to test the drug in other autoimmune diseases and inflammatory conditions, including dermatological disorders and diabetes.
Alopecia areata causes sudden hair loss and can have a significant negative impact on a patient&#8217;s quality of life and psychological health.
&#8220;The FDA&#8217;s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative immunotherapeutic treatment of autoimmune diseases. This trial is a milestone for our Company, and the beginning of clinical development of treatments for quality-of-life indications,&#8221; said Dr. Hing C. Wong, Founder and CEO of HCW.
HCW stock is trading on higher than normal session volume at 311.50 million shares. The company&#8217;s average session volume over the past 100 days is 9.61 million shares, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
See Also: <a href="https://www.benzinga.com/25/02/43443639/nike-to-rally-around-24-here-are-10-top-analyst-forecasts-for-monday">Nike To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday</a>
HWCB Price Action: At the time of writing HCW stock is trading 138.7% higher at 66 cents, per data from<a href="https://www.benzinga.com/pro/"> Benzinga Pro</a>.
Image: via Shutterstock

Comments

HyperBlock

Noticias

Últimas noticias sobre HyperBlock (OTC:HYBOF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL